[5-(2,4-dimethoxy-benzyloxycarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-yl methyl ester | 1235975-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: [5-(2,4-dimethoxy-benzyloxycarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-yl methyl ester
• 英文别名: [5-(2,4-dimethoxy-benzyloxycarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-ylmethyl ester；9H-fluoren-9-ylmethyl N-[6-[(2,4-dimethoxyphenyl)methoxyamino]-6-oxohexyl]carbamate
• CAS: 1235975-95-7
• 化学式: C₃₀H₃₄N₂O₆
• 分子量: 518.61
• InChiKey: LMMHWAHVXMTZFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  38
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [5-(2,4-dimethoxy-benzyloxycarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-yl methyl ester 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以56%的产率得到6-amino-hexanoic acid (2,4-dimethoxy-benzyloxy)-amide
  参考文献：
  名称：

  [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES
  [FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE

  摘要：

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。

  公开号：

  WO2005040101A1
• 作为产物：
  描述：

  芴甲氧羰酰基-6-氨基己酸 、 O-(2,4-二甲氧基苄基)羟胺 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 [5-(2,4-dimethoxy-benzyloxycarbamoyl)-pentyl]-carbamic acid 9H-fluoren-9-yl methyl ester
  参考文献：
  名称：

  [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES
  [FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE

  摘要：

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。

  公开号：

  WO2005040101A1

文献信息

• [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES<br/>[FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE
  申请人：S BIO PTE LTD

  公开号：WO2005040101A1

  公开（公告）日：2005-05-06

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。
• Acylurea Connected And Sulfonylurea Connected Hydroxamates
  申请人：Lim Ze-Yi

  公开号：US20080070954A1

  公开（公告）日：2008-03-20

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.

  本发明涉及羟酰胺化合物，其为组蛋白去乙酰化酶的抑制剂。更具体地说，本发明涉及含有酰基脲/磺酰基脲的化合物及其制备方法。这些化合物可能作为药物用于治疗增殖性疾病以及其他涉及或与具有组蛋白去乙酰化酶活性的酶相关的疾病。
• Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity
  作者：Haishan Wang、Ze-Yi Lim、Yan Zhou、Melvin Ng、Ting Lu、Ken Lee、Kanda Sangthongpitag、Kee Chuan Goh、Xukun Wang、Xiaofeng Wu、Hwee Hoon Khng、Siok Kun Goh、Wai Chung Ong、Zahid Bonday、Eric T. Sun

  DOI：10.1016/j.bmcl.2010.04.041

  日期：2010.6

  Thirty-six novel acylurea connected straight chain hydroxamates were designed and synthesized. Structure-activity relationships (SAR) were established for the length of linear chain linker and substitutions on the benzoylurea group. Compounds 5g, 5i, 5n, and 19 showed 10-20-fold enhanced HDAC1 potency compared to SAHA. In general, the cellular potency pIC(50) (COLO205) correlates with enzymatic potency pIC50 ( HDAC1). Compound 5b (SB207), a structurally simple and close analogue to SAHA, is more potent against HDAC1 and HDAC6 compared to the latter. As a representative example of this series, good in vitro enzymatic and cellular potency plus an excellent pharmacokinetic profile has translated into better efficacy than SAHA in both prostate cancer (PC3) and colon cancer (HCT116) xenograft models. (C) 2010 Elsevier Ltd. All rights reserved.